Journal of Vaccines & Vaccination

Department of Medical Oncology, Arturo López Pérez Foundation Oncological Institute, Santiago, Metropolitan Region, Chile

Biography

Mauricio Mahave is currently working as a Professor in the Department of Medicine. Mauricio Mahave is serving as an editorial member and reviewer of several international reputed journals. Mauricio Mahave has successfully completed his Administrative responsibilities His research interests includes Medicine. Mauricio Mahave  has authored of many research articles/books related to Medicine.

Publications

• Research Article   
  Convalescent Plasma in COVID-19; Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial
  Author(s): Raimundo Gazitua*, Jose Luis Briones, Carolina Selman, Franz Villarroel-Espíndola, Adam Aguirre-Ducler, Roxana Gonzalez-Steigmaier, Karina Cereceda, Mauricio Mahave, Ricardo Morales, Fernanda Yarad, Nicolas Yannez, María Elvira Balcells, Luis Rojas, Bruno Nervi, Jyh Kae Nien, Javier Garate, Carolina Prieto, Sofía Palma, Carolina Escobar, Josefina Bascuñán, Rodrigo Muñoz, Mónica Pinto, Daniela Cardemil, Marcelo Navarrete, Soledad Reyes, Victoria Espinosa, Betzabé Rubio, Pedro Ferrer-Rosende, Jorge Sapunar, Hugo Marsiglia and Christian Caglevic
  
  Background: The use of Convalescent Plasma (CP) to treat COVID-19 has shown promising results; however, its effectiveness remains uncertain. The purpose of this study was to determine the safety and mortality of CP among patients hospitalized with COVID-19. Study design and methods: This multicenter, open-label, uncontrolled clinical trial is currently being conducted at nine hospitals in Chile. Patients hospitalized due to COVID-19 with less than 14 days since symptom onset were eligible. Enrolled patients were classified into four groups: Patients with cancer and severe COVID-19. Patients with cancer and non-severe COVID-19. Patients with severe COVID-19 and patients with non-severe COVID-19 only. The intervention involved two 200-cc. CP transfusions with anti-SARS-CoV-2 IgG titers ≥ 1:320 collected from COVID-19-reco.. View more»
  

  DOI: 10.35248/2157-7560.21.s12.002

  Abstract HTML PDF